21754 Federal Register / Vol. 76, No. 74 / Monday, April 18, 2011 / Notices 

SUMMARY: The Health Resources and 

Services Administration (HRSA) will be 

issuing non-competitive supplemental 

funding to the Maternal Child and 

Health Bureau’s (MCHB) 

Comprehensive Hemophilia Diagnostic 

and Treatment Centers. MCHB’s 

Division of Children with Special 

Health Needs and the Genetic Services 

Branch are currently undergoing a 

strategic planning process. This will 

provide feasible time for the MCHB to 

align fiscal resources and programmatic 

goals as determined by this strategic 

planning process with the least 

disruption to the States, communities, 

and constituencies that currently 

receive assistance and services from 

these grantees. 

SUPPLEMENTARY INFORMATION: Intended 

Recipient of the Award: Comprehensive 

Hemophilia Diagnostic and Treatment 

Centers—12 Regional Centers (see table 

below). 

Amount of the Award: 12 awards 

ranging from $184,846 to $595,453. 

CFDA Number: 93.110. 

Project Period: The period of 

supplemental support is from June 1, 

2011, to May 31, 2012. 

Authority: This activity is under the 

authority of Section 501(a) (2) of the Social 

Security Act, the Maternal and Child Health 

Federal Set-Aside Program: Special Projects 

of Regional and National Significance 

(SPRANS) (42 U.S.C. 701). 

REGIONAL COMPREHENSIVE HEMOPHILIA DIAGNOSTIC AND TREATMENT CENTERS

Grantee Grant No. Region 

FY 2010 

Funding 

Level 

University of Massachusetts ............................................... H30 MC00037– 

12–00.

Region 1 .............................................................. $312,472 

Mt. Sinai School of Medicine .............................................. H30 MC00019– 

20–00.

Region 2 .............................................................. 595,453 

Children’s Hospital of Philadelphia ..................................... H30 MC09625– 

02–00.

Region 3 .............................................................. 530,808 

University of North Carolina ................................................ H30 MC05053– 

07–01.

Region 4–N ......................................................... 329,980 

Hemophilia of Georgia ........................................................ H30 MC00011– 

20–00.

Region 4–S ......................................................... 228,857 

Hemophilia Foundation of Michigan .................................... H30 MC00015– 

20–00.

Region 5–E ......................................................... 365,256 

Great Lakes Hemophilia Foundation .................................. H30 MC00032– 

21–02.

Region 5–W ........................................................ 446,520 

University of Texas HSC at Houston .................................. H30MC00029–20– 

06.

Region 6 .............................................................. 455,871 

Children’s Mercy Hospital ................................................... H30 MC00040– 

10–00.

Region 7 .............................................................. 371,228 

University of Colorado ......................................................... H30 MC00008– 

20–00.

Region 8 .............................................................. 321,921 

Children’s Hospital of Orange County ................................ H30 MC00036– 

12–00.

Region 9 .............................................................. 714,832 

Oregon Health and Science University ............................... H30 MC00025– 

20–00.

Region 10 ............................................................ 184,846 

Justification for the Exception to 

Competition 

Since the inception of HRSA’s genetic 

services program, the landscape of our 

health care system has changed 

dramatically. In addition, our 

knowledge base for genetic medicine in 

general and blood disorders in 

particular has expanded. Unfortunately, 

the changes in our knowledge base and 

standards of care are not currently 

reflected in what we measure through 

this program nor how they are 

integrated into day to day activities that 

influence the health of individuals with 

hemophilia, thrombophilia and von 

Willebrand Disease and other congenital 

bleeding disorders. 

To better reflect the current 

landscape, the MCHB is undertaking a 

strategic planning process this year. At 

the end of the process, we hope to have 

better defined measures that will reflect 

our new plan and the goals for the next 

10 years. This will provide us with the 

basis to expand the applicant pool as 

well as improve the evidence base for 

the utility of the National Hemophilia 

Program. 

MCHB proposes this course of action 

for three reasons: (1) To appropriately 

respond to the directions that will be 

outlined after the strategic planning 

process, (2) to provide for sufficient 

fiscal resource to continue 

programmatic activities at current 

levels, and (3) to maintain MCH 

programmatic support with the least 

disruption to the State, community, and 

MCH constituencies who are currently 

receiving assistance and services from 

these grantees and the grantees 

themselves. Without this approach, the 

programmatic changes indicated 

through the strategic planning process 

will not be outlined nor implemented 

for another 3 years when the next 

competitive process will begin. Delaying 

the competition into mid fiscal year 

2011 ensures continuity of funding for 

all eligible entities, with no eligible 

entity being harmed by the extension. 

FOR FURTHER INFORMATION CONTACT: Sara 

Copeland, M.D., Maternal and Child 

Health Bureau, Health Resources and 

Services Administration, Room 18A–19, 

Parklawn Building, 5600 Fishers Lane, 

Rockville, Maryland 20857, Telephone 

(301) 443–8860, scopeland@hrsa.gov. 

Dated: April 12, 2011. 

Mary K. Wakefield, 

Administrator. 

[FR Doc. 2011–9269 Filed 4–15–11; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 


erowe on DSK5CLS3C1PROD with NOTICES
Federal Register / Vol. 76, No. 74 / Monday, April 18, 2011 / Notices 21755 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Preclinical Services for the 

Development of Biopharmaceutical Products 

for Infectious Diseases. 

Date: May 11, 2011. 

Time: 12 p.m. to 6 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6610 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Yong Gao, PhD, Scientific 

Review Officer, Scientific Review Program, 

DHHS/NIH/NIAID, 6700B Rockledge Drive, 

Room 3246, Bethesda, MD 20892, 301–443– 

8115, gaol2@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Immune Response to Viral 

Infections. 

Date: May 12, 2011. 

Time: 11 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817. 

(Telephone Conference Call.) 

Contact Person: Richard W. Morris, PhD, 

Scientific Review Officer, Scientific Review 

Program, DEA/NIAID/NIH/DHHS, Room 

2217, 6700–B Rockledge Drive, MSC–7616, 

Bethesda, MD 20892–7616, 301–496–2550, 

rmorris@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: April 12, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–9322 Filed 4–15–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of a meeting of the 

Director’s Council of Public 

Representatives. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Director’s Council of 

Public Representatives. 

Date: May 6, 2011. 

Time: 1:30 p.m. to 3:30 p.m. 

Agenda: The Council will discuss issues 

related to how best to gather input from the 

public as well as how COPR can assist in 

promoting K–12 education. Further 

information will be available on the COPR 

Web site. 

Place: National Institutes of Health, 

Building 31, Conference Room 6, 31 Center 

Drive, Bethesda, MD 20892. 

Contact Person: Sheria Washington, 

Executive Secretary/Outreach Program 

Specialist, Office of Communications and 

Public Liaison, Office of the Director, 

National Institutes of Health, 1 Center Drive, 

Room 331, Bethesda, MD 20892, 301–594– 

4837, Sheria.Washington@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.copr.nih.gov, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS.) 

Dated: April 12, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–9320 Filed 4–15–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

[DHS Docket No. DHS–2009–0032] 

Guidance to Federal Financial 

Assistance Recipients Regarding Title 

VI Prohibition Against National Origin 

Discrimination Affecting Limited 

English Proficient Persons 

AGENCY: Office for Civil Rights and Civil 

Liberties, DHS. 

ACTION: Notice; final policy guidance. 

SUMMARY: The Department of Homeland 

Security is finalizing guidance to 

recipients of Federal financial assistance 

regarding Title VI’s prohibition against 

national origin discrimination affecting 

persons with limited English proficient 

persons. This guidance is issued 

pursuant to Executive Order 13166 and 

is consistent with government-wide 

guidance previously issued by the 

Department of Justice. 

DATES: This guidance is effective May 

18, 2011. 

FOR FURTHER INFORMATION CONTACT: 

Rebekah Tosado, Senior Advisor to the 

Officer for Civil Rights and Civil 

Liberties, Office for Civil Rights and 

Civil Liberties, Department of Homeland 

Security, 245 Murray Lane, SW., 

Building 410, Washington, DC 20528, 

Mail Stop 0190. Toll free: 1–866–644– 

8360 or TTY 1–866–644–8361. Local: 

202–401–1474 or TTY: 202–401–0470. 

SUPPLEMENTARY INFORMATION: Executive 

Order 13166 directs each Federal agency 

that extends assistance subject to the 

requirements of Title VI of the Civil 

Rights Act of 1964, 42 U.S.C. 2000d, et 

seq., to publish guidance for its 

respective recipients clarifying that 

obligation. Executive Order 13166, 

Improving Access to Services for 

Persons with Limited English 

Proficiency, 65 FR 50121 (August 11, 

2000). Executive Order 13166 further 

directs that all such guidance 

documents be consistent with the 

compliance standards and framework 

detailed by the Department of Justice 

(DOJ). See Enforcement of Title VI of the 

Civil Rights Act of 1964—National 

Origin Discrimination Against Persons 

with Limited English Proficiency, 65 FR 

50123 (August 16, 2000) (DOJ Agency 

LEP Guidance). 

The Department of Homeland 

Security (DHS) adopts guidance that 

adheres to the Government-wide 

compliance standards and framework 

detailed in the DOJ Agency LEP 

Guidance and in the DOJ’s own 

guidance to its financial assistance 

recipients. Guidance to Federal 

Financial Assistance Recipients 


erowe on DSK5CLS3C1PROD with NOTICES